UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note released on Monday, Benzinga reports. They currently have a $54.00 price target on the stock.

Separately, Oppenheimer cut their target price on UroGen Pharma from $35.00 to $34.00 and set an outperform rating for the company in a research note on Friday, March 15th.

UroGen Pharma Price Performance

Shares of NASDAQ:URGN opened at $12.97 on Monday. The business’s 50 day moving average price is $14.91 and its 200-day moving average price is $14.69. The firm has a market capitalization of $304.20 million, a PE ratio of -3.48 and a beta of 1.09. UroGen Pharma has a 1 year low of $8.69 and a 1 year high of $24.13.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The business had revenue of $23.53 million during the quarter, compared to the consensus estimate of $22.30 million. As a group, analysts expect that UroGen Pharma will post -3.59 earnings per share for the current year.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 12,000 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the transaction, the insider now owns 139,437 shares in the company, valued at $1,959,089.85. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 11.13% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of URGN. Allspring Global Investments Holdings LLC purchased a new stake in UroGen Pharma in the third quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. grew its holdings in UroGen Pharma by 361.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company’s stock worth $54,000 after acquiring an additional 2,801 shares during the period. SG Americas Securities LLC purchased a new position in shares of UroGen Pharma in the 4th quarter valued at about $131,000. Federated Hermes Inc. acquired a new stake in shares of UroGen Pharma during the 3rd quarter valued at approximately $184,000. Finally, Sierra Summit Advisors LLC acquired a new stake in UroGen Pharma in the fourth quarter valued at $218,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.